Celularity Inc — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Celularity Inc. (market cap ~$28.4M) executed a securities purchase agreement dated September 23, 2026, issuing senior secured convertible notes with a $1.50 conversion price and warrants to purchasers including Philip Daniele Barach Family Trust. The $3M existing convertible note from December 2025 was amended and restated into the new transaction structure. Notes mature 24 months from amendment date with 10% regular interest (15% on default), convertible at holder option or mandatorily upon qualified financing or stock price reaching $6.00 for 30 consecutive trading days. No specific aggregate deal size disclosed in exhibits.
Why this rating
Debt financing meaningful for $28.4M company; conversion price $1.50 vs. typical micro-cap equity values. Structured transaction with board seats suggests investor control concerns but likely necessary for survival.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.